On June 13, 2024, the U.S. Supreme Court unanimously ruled in FDA v. Alliance for Hippocratic Medicine that the plaintiffs, anti-abortion doctors and advocacy groups, lacked legal standing to challenge the FDA’s approval and regulation of mifepristone. Without proving personal or concrete harm, the plaintiffs could not meet the threshold required under Article III of the Constitution. As a result, the Court did not consider the drug’s safety or the legality of the FDA’s decisions, allowing existing access to mifepristone to remain in place.
What Is Mifepristone?
Mifepristone is a prescription medication approved by the Food and Drug Administration (FDA) in 2000 to terminate early pregnancies. It is used in combination with misoprostol. The FDA’s regulations have evolved over the years:
- In 2016, the agency extended the drug’s usage window from 7 to 10 weeks of pregnancy and allowed qualified non-physicians to prescribe it.
- In 2021, the FDA permanently removed the in-person dispensing requirement, permitting prescriptions via telemedicine and delivery by mail.
These updates helped expand access to abortion care, especially in rural and underserved communities. By 2024, medication abortion accounted for 63% of all abortions in the United States.
The Legal Challenge: Plaintiffs’ Arguments and the Court’s Rationale
The plaintiffs, several doctors and the Alliance for Hippocratic Medicine, argued that the FDA unlawfully approved and deregulated mifepristone. They claimed that easier access to the drug could indirectly harm them, such as by requiring them to treat patients with complications in emergency settings.
However, the Supreme Court disagreed. Writing for the Court, Justice Brett Kavanaugh stated that the plaintiffs could not demonstrate a direct injury traceable to the FDA’s actions. Since they did not prescribe mifepristone or interact with it professionally, their objections were speculative and insufficient for standing.
“Federal courts do not exist to resolve general grievances or ideological disputes. Plaintiffs must show a concrete, particularized injury,” wrote Justice Kavanaugh.
As a result, the case was dismissed without the Court ruling on whether the FDA’s actions were proper or whether mifepristone is safe.
Expert Testimony Challenged: Spotlight on Dr. Ingrid Skop
Throughout the litigation, the plaintiffs relied heavily on testimony from Dr. Ingrid Skop, a practicing OB-GYN affiliated with the Charlotte Lozier Institute. Her credibility as an expert witness came under scrutiny.
In Planned Parenthood of Southwest & Central Florida v. State, a 2022 Florida case, the circuit court judge ruled that Dr. Skop’s claims about abortion risks were “inaccurate and overstated.” During her testimony, she admitted she was “not a really good researcher.” The judge also noted her conclusions lacked scientific rigor and deviated from the mainstream medical consensus.
This undermined the reliability of her testimony under the Daubert standard, which requires that expert opinions be based on reliable methodology and peer-reviewed evidence.
Impact of the Ruling
1. FDA Authority Reinforced
The decision reaffirms the FDA’s role as the scientific regulator of medications. The Court declined to second-guess the agency’s scientific determinations in the absence of direct harm to the plaintiffs. This reinforces the legal deference courts typically afford to administrative agencies like the FDA.
2. Continued Access to Mifepristone
FDA rules permitting the use of mifepristone through 10 weeks of pregnancy, prescriptions by non-physicians, and mail-order dispensing remain in effect. Patients in states where abortion remains legal can continue accessing mifepristone through telemedicine, a critical option for those in remote or underserved regions.
3. Limiting Ideological Lawsuits
By emphasizing the need for a personal and direct injury, the Court signaled that ideological disagreements alone are insufficient grounds for litigation. This precedent may limit future lawsuits seeking to block medical procedures or drugs based solely on moral or political objections.
Scientific and Medical Consensus
Although the Court did not rule on the safety of mifepristone, medical consensus overwhelmingly supports its safety and efficacy. Studies consistently show that serious complications from mifepristone are rare, less than 0.4%. It has been used by more than five million individuals in the United States since its approval.
In May 2025, the American College of Obstetricians and Gynecologists (ACOG) and several other medical organizations reaffirmed that mifepristone is safe and essential for reproductive health. Their joint statement highlighted that claims suggesting otherwise are based on flawed or ideologically driven studies.
Ongoing Legal Developments
The Supreme Court ruling does not end all litigation involving mifepristone. Several states, including Idaho, Missouri, and Kansas, have filed lawsuits based on Medicaid funding and administrative law concerns. These cases, which raise different legal questions, continue in federal courts and could eventually reach appellate review.
Secure the Right Expert Witness with ForensisGroup
Navigating the complexities of the Daubert standard can be challenging, but having the right expert witness on your side makes all the difference. At ForensisGroup, we provide access to over 3,000 rigorously vetted experts across a wide range of fields. Our experts are not only highly qualified but also have the experience and credibility to withstand Daubert challenges.
Partner with ForensisGroup today to ensure your expert witnesses are prepared to meet the Daubert standard and bring reliable, scientifically sound testimony to your case.
Visit ForensisGroup for more information on securing the right expert witness for your case.
